株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の大腸癌スクリーニング市場:成長、動向、および予測(2020年~2025年)

Colorectal Cancer Screening Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 613020
出版日 ページ情報 英文 115 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=113.11円で換算しております。
Back to Top
世界の大腸癌スクリーニング市場:成長、動向、および予測(2020年~2025年) Colorectal Cancer Screening Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年01月01日 ページ情報: 英文 115 Pages
担当者のコメント
下記の日本語概要は、最新版レポートの内容と異なる場合があります。詳細はお問合せください。
概要

世界の大腸癌スクリーニング市場の主な成長要因には、効果的な遺伝子検査の出現、大腸癌の有病率の増加、および癌予防の取り組みの増加などが挙げられます。また、グアヤック法便潜血検査(gFOBT)を使用した大腸スクリーニング市場は、製品の入手しやすさと低コストにより急成長が予測されています。

当レポートは世界の大腸癌スクリーニング市場について調査しており、市場機会や動向、成長および阻害要因、スクリーニングテスト・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • 有効な遺伝子検査の出現
    • 大腸癌の有病率の増加
    • 増加する癌予防の取り組み
  • 市場阻害要因
    • スクリーニングテストの高いコスト
    • 新興国における医療への不十分なアクセス
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • スクリーニングテスト別
    • スツールベースの検査
    • 大腸内視鏡検査
    • CTコロノグラフィー(バーチャル大腸内視鏡検査)
    • 軟性S状結腸鏡検査
    • その他
  • エンドユーザー別
    • 病院
    • 独立した診断ラボ
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Abbott Laboratories
    • Clinical Genomics Technologies Pty Ltd
    • Epigenomics Inc.
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche AG
    • Hemosure Inc.
    • Novigenix SA
    • Quidel Corporation
    • Siemens Healthcare Private Limited
    • Sysmex Corporation

第7章 市場機会および今後の動向

目次
Product Code: 55100

Market Overview

The major factors for the growth of the colorectal cancer screening market include the advent of efficacious genetic tests, an increase in the prevalence of colorectal cancer, and increasing cancer prevention initiatives.

Most of the Colorectal Cancer (CRC) cases exhibit familial clustering, which means that tens of thousands of individuals have a disease with a potentially definable genetic component. The risk of CRC is higher in people with a strong family history of colorectal cancer, i.e., inherited colon cancer syndromes. The genetic tests developed for colon cancer include hereditary nonpolypsis colon cancer (HNPCC) test, familial adenomatous polyposis (FAP) test, etc. Genetic testing for colon cancer creates better opportunities for early diagnosis. For instance, the most common genetic changes related to colon cancer are familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC). These genetic changes could be identified at a very early age, less than 40 years through genetic testing. If these medical screenings are employed, the number of colon cancer cases found in the early stages may increase. Also, gene therapies to alter these mutations are likely to be developed. According to a research article published in 2017, "Colorectal cancer screening: An updated review of the available options", it was estimated that colon cancer incidence and mortality are declining over the past decade, owing to the adoption of effective screening methods, like Fecal DNA test and Blood DNA test. The increasing awareness about genetic screening methods and advantages for undergoing these tests (not only for early detection and treatment, but also for the removal of precancerous cells, which are much cheaper than the usual run of chemotherapy) are driving the colorectal cancer screening market.

Scope of the Report

As per the scope of this report, colorectal cancer (CRC) is known as bowel cancer and colon cancer. It is the development of cancer from the colon or rectum. Colorectal cancer (CRC) screening tests use kits and various medical devices for diagnosing cancer. The market is segmented by screening tests, end user, and geography.

Key Market Trends

Guaiac Fecal Occult Blood Test (gFOBT) is Expected to be the Fastest Growing Segment

The guaiac fecal occult blood test (gFOBT) is one of the several methods that is used to detect colorectal cancer. The test involves the detection of hidden blood in the feces, and identifies the presence of cancer cells or tumours in the colon or rectum. The test involves placing a small sample of stool on specially guaiac coated cards, and then sent to a laboratory for testing. Upon putting a testing solution on the cards, the guaiac causes the stool sample to change colour. The colour changes very quickly if there is blood in the stool. Presence of blood in the stool may be a sign of colorectal cancer or other problems, such as polyps, ulcers, or hemorrhoids. As per the American College of Gastroenterology (ACG), the procedural volumes for colorectal (CRC) screening with gFOBT have decreased modestly. However, the factors that are driving the market are its ease of availability, low cost, and coverage in the insurance, along with being sold as over-the-counter. Also, with product innovation, the method has become reliable. The growth of the market is mainly attributed to the ease of availability and low cost of the products.

North America is Expected to Dominate the Market

According to the United States National Cancer Statistics, colon cancer is reported to be America's second-deadliest cancer with 50,000 deaths, annually, followed by lung cancer. It was estimated that approximately 1, 44,000 cases of colorectal cancer were found in 2015, and nearly 1, 60, 000 new cases for colorectal cancer are expected to occur by 2020. This increase in the disease occurrence may eventually increase the demand for colorectal cancer screening procedures. Several companies are coming up with advanced screening procedures, including genetic tests, which are gaining acceptability in the US market. According to the National Health Interview Survey, CRC screening (in accordance with guidelines among adults of 50 years and more) increased from 34%, in 2000, to 63%, in 2015. Initiatives, like national TV campaigns, digital marketing, primary care sales force, collated materials, clinical and health publications, etc., are helping increase the adoption of the colorectal cancer screening procedures in the United States. Also, government initiatives are increasing awareness, which is playing an integral role and driving the market for colorectal cancer screening in the country. According to the American Cancer Society, the colon cancer screening rate was 59% in 2010, and increased to 62% in 2015. This rate is increasing at a steady pace, and the goal for colon cancer screening is to reach 80% by 2018. Increasing number of colorectal cancer incidences in the United States, along with several educational and financial initiatives, are expected to increase the colorectal cancer screening market in the United States, in the future.

Competitive Landscape

The market studied is a moderately consolidated market, owing to the presence of many small and large market players. Some of the market players are Abbott Laboratories, Clinical Genomics Technologies Pty Ltd, Epigenomics Inc., Exact Sciences Corporation, F. Hoffmann-La Roche AG, Hemosure Inc., Novigenix SA, Quidel Corporation, Siemens Healthcare Private Limited, and Sysmex Corporation.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Advent of Efficacious Genetic Tests
    • 4.2.2 Increase in Prevalence of Colorectal Cancer
    • 4.2.3 Increasing Cancer Prevention Initiatives
  • 4.3 Market Restraints
    • 4.3.1 High Screening Tests Costs
    • 4.3.2 Inadequate Healthcare Access in Developing Countries
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Screening Tests
    • 5.1.1 Stool-based Tests
      • 5.1.1.1 Fecal Immunochemical Test (FIT)
      • 5.1.1.2 Guaiac-based Fecal Occult Blood Test (gFOBT)
      • 5.1.1.3 Stool DNA Test
    • 5.1.2 Colonoscopy
    • 5.1.3 CT Colonography (Virtual Colonoscopy)
    • 5.1.4 Flexible Sigmoidoscopy
    • 5.1.5 Others
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Independent Diagnostic Labs
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Clinical Genomics Technologies Pty Ltd
    • 6.1.3 Epigenomics Inc.
    • 6.1.4 Exact Sciences Corporation
    • 6.1.5 F. Hoffmann-La Roche AG
    • 6.1.6 Hemosure Inc.
    • 6.1.7 Novigenix SA
    • 6.1.8 Quidel Corporation
    • 6.1.9 Siemens Healthcare Private Limited
    • 6.1.10 Sysmex Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top